Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Economic and Clinical Impact Evaluation of AI-Aided Point-of-Care Ultrasound (POCUS) in the Management of Early-Stage Joint Damage in Hemophilia

Azusa Nagao, Kunihiko Kido, Yoichi Nakamoto, Yuta Yoshida, Katsuyuki Fukutake

Blood (2023) 142 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2023-173290

Published: 2023

Journal Articles

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

Azusa Nagao, Yusuke Inagaki, Keiji Nogami, Naoya Yamasaki, Fuminori Iwasaki, Yang Liu, Yoichi Murakami, Takahiro Ito, Hideyuki Takedani

Blood (2023) 142 (Supplement 1): 3645.

https://doi.org/10.1182/blood-2023-174054

Published: 2023

Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2023-173071

Published: 2023

Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami

Blood (2023) 142 (Supplement 1): 3991.

https://doi.org/10.1182/blood-2023-173073

Published: 2023

Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami

Blood (2022) 140 (Supplement 1): 2742–2744.

https://doi.org/10.1182/blood-2022-157249

Published: 2022

Journal Articles

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Midori Shima, Masashi Taki, Rie Shirayama, Tadashi Matsushita, Yasuharu Nishida, Azusa Nagao, Yoshiyuki Ogawa, Kazuo Kawasugi

Blood (2022) 140 (Supplement 1): 11304–11305.

https://doi.org/10.1182/blood-2022-167449

Published: 2022

Journal Articles

Hikoboshi Study: Remaining Burden and Current Medical Care Status of Patients with Congenital Hemophilia a: A Study Using Two Japanese Medical Information Databases

Azusa Nagao, Akiko Ioka, Takao Nakamura, Yoichi Murakami, Misako Makishima, Norihiro Okada, Michio Sakai

Blood (2021) 138 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2021-144467

Published: 2021

NARROW

Economic and Clinical Impact Evaluation of AI-Aided Point-of-Care Ultrasound (POCUS) in the Management of Early-Stage Joint Damage in Hemophilia

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Hikoboshi Study: Remaining Burden and Current Medical Care Status of Patients with Congenital Hemophilia a: A Study Using Two Japanese Medical Information Databases

Email alerts

ASH Publications

American Society of Hematology

Economic and Clinical Impact Evaluation of AI-Aided Point-of-Care Ultrasound (POCUS) in the Management of Early-Stage Joint Damage in Hemophilia

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Hikoboshi Study: Remaining Burden and Current Medical Care Status of Patients with Congenital Hemophilia a: A Study Using Two Japanese Medical Information Databases

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only